Lycia Sets IPO Terms to Finance Clinical LYTAC Proof-of-Concept

Company Lycia Therapeutics Event Type Financing (Proposed Initial Public Offering, S-1/A terms) Modality Lysosome-targeting chimeras (LYTAC); catalytic extracellular degraders Asset LCA-0061; LCA-0062; LCA-0321 Target IgE (LCA-0061, LCA-0062); TSH receptor autoantibodies (LCA-0321) Disease Area Food allergy; Graves disease Summary Lycia Therapeutics filed terms for a proposed…